INSM — Insmed Incorporated
$93.39-1.76%
Last close: · regular session
Last 60 sessions
INSM closed at $93.39 (-1.76%) on Oct 23, 2026. Active automatic shelf (S-3ASR, May 2026). Float: 214.3M shares. Latest SEC filing: SCHEDULE 13G/A on Aug 6, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for INSM in the TickerWise workspace.
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 1,271
- Website: https://www.insmed.com
Latest SEC filings for INSM
Latest INSM news
- Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Read article
- Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 Read article
- This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Read article
- INSM Stock Slides on CFO Exit, Reiterates '26 Sales View Read article
- Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed Read article
- Insmed CFO Sara Bonstein to step down, reaffirms guidance Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.